Meters & MonitorsBlood Glucose Meters Current Continuous Monitors Comparison of Available Monitors ![]() Various Future Monitors Improving Today's Meters Other Monitors Older Monitors
Other MonitorsDiagnoptics SenseWear
DiagnOptics
The AGE Reader Dr. Smith began the first clinical studies in diabetes and renal failure at the University Hospital in Groningen. After filing the patent application for the AGE Reader™ in 1999, DiagnOptics was established in 2003 and CE certification for the AGE Reader™ was received in 2006. Currently the company is working on obtaining additional regulatory approvals in other regions and is engaged in new product development activities. About A.G.E. (Advanced Glycation Endproducts) AGEs are key players in glycemic and oxidative stress, and have been shown to be an important indicator of many age-related diseases, such as atherosclerosis, diabetes, renal failure and Alzheimer. The amount of AGEs in tissue serves as an important risk predictor of diabetes and its complications. AGEs normally accumulate with ageing, but this process occurs more rapidly when glucose levels rise and in renal failure. The accumulation of AGEs can initiate a wide range of abnormal responses in cells and tissues such as an increased burden of death and diseases of heart and blood vessels. Skin AGE's, determined in skin tissue samples, correlate closely with early kidney, eye and nerve disease in patients with diabetes. AGE Reader Technology Prior to development of the AGE Reader, it had been complicated to measure tissue AGEs because existing methods were expensive, time consuming, lack specificity, are poorly reproducible and/or are invasive. Although there is currently no gold standard for AGEs measurements, the AGE Reader™ is the only diagnostic device that non-invasively diagnoses and assesses the risk of diabetes and its cardiovascular, nephrological and neurological complications through measuring tissue accumulation of AGEs. It provides information so the physician can focus treatment on patients with the highest risk of complications. A light source excites fluorescent moieties in the tissue of interest which then emits light of a different wavelength. In the wavelength band that is used, the major contribution in fluorescence comes from fluorescent AGEs linked mostly to collagen, but also to other proteins and lipids. The emitted light is detected using a spectrometer. By using specific technical adaptations including selection of specific wavelength, modulated or pulsed light sources, a more selective discrimination of specific AGEs can be obtained.
![]()
For more information, contact DiagnOptics. Click Here to browse our secure, on-line store for a complete selection of diabetes books at 22%-50% off their cover price. You can also download our Diabetes Mall 2008 Catalog, email our Order Form, or call us at (800) 988-4772. |


Other Monitors

